Skip to content
OpenCapital
Get started

Fate Therapeutics FATE Q2 2025 earnings

Reported August 12, 2025 · Before market open

Revenue$1.9MBeat by $758.1KDiluted EPS-$0.29Beat by $0.06
Revenue estimate$1.1M
EPS estimate-$0.35

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$1.4M
EPS estimate-$0.28

Versus estimates

Revenue

Q1 2026$1.3MMiss by $192.9KQ4 2025$1.4MBeat by $32.4KQ3 2025$1.7MBeat by $542.9K
Q2 2025$1.9MBeat by $758.1K
Q1 2025$1.6MBeat by $444.6KQ4 2024$1.9MBeat by $291.3K

Diluted EPS

Q1 2026-$0.26Beat by $0.03Q4 2025-$0.27In lineQ3 2025-$0.27Beat by $0.02
Q2 2025-$0.29Beat by $0.06
Q1 2025-$0.32Beat by $0.07Q4 2024-$0.31Beat by $0.13

Ask the moment Fate Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Fate Therapeutics report Q2 2025 earnings?
Fate Therapeutics (FATE) reported Q2 2025 earnings on August 12, 2025 before market open.
What were Fate Therapeutics's Q2 2025 revenue and EPS?
Fate Therapeutics reported revenue of $1.9M and diluted EPS of $-0.29 for Q2 2025.
Did Fate Therapeutics beat estimates in Q2 2025?
Revenue beat the consensus estimate of $1.1M by $758.1K. EPS beat the consensus estimate of $-0.35 by $0.06.
How did Fate Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 71.8% from $6.8M a year earlier and diluted EPS grew 12.1% from $-0.33.
Where can I find Fate Therapeutics's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-107309) directly on SEC EDGAR. The filing index links above go to sec.gov.